fenofibrate has been researched along with Peripheral Arterial Diseases in 3 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aims of this study were, firstly, to assess the effect of concurrent peripheral artery disease (PAD) on the health-related quality of life (QOL) of people diagnosed with a small abdominal aortic aneurysm (AAA); and secondly, to test whether the peroxisome proliferator-activated receptor α agonist fenofibrate improved QOL of people diagnosed with a small AAA, including those diagnosed with concurrent PAD." | 7.96 | Health-related quality of life amongst people diagnosed with abdominal aortic aneurysm and peripheral artery disease and the effect of fenofibrate. ( Golledge, J; Jenkins, JS; Moxon, JV; Pinchbeck, J; Quigley, F; Rowbotham, SE; Yip, L, 2020) |
| "These case reports aim to show that hyperfibrinogenemia is a risk factor for the progression and prognosis of peripheral arterial disease (PAD), in patients with and without diabetes mellitus type 2." | 7.88 | Hyperfibrinogenemia in Peripheral Arterial Disease: Coexistent and Independent Risk Factor (A Report of Two Cases and Review of Literature). ( Antova, E; Bosevska, G; Bosevski, M; Krstevski, G; Mitevska, I, 2018) |
| "The aims of this study were, firstly, to assess the effect of concurrent peripheral artery disease (PAD) on the health-related quality of life (QOL) of people diagnosed with a small abdominal aortic aneurysm (AAA); and secondly, to test whether the peroxisome proliferator-activated receptor α agonist fenofibrate improved QOL of people diagnosed with a small AAA, including those diagnosed with concurrent PAD." | 3.96 | Health-related quality of life amongst people diagnosed with abdominal aortic aneurysm and peripheral artery disease and the effect of fenofibrate. ( Golledge, J; Jenkins, JS; Moxon, JV; Pinchbeck, J; Quigley, F; Rowbotham, SE; Yip, L, 2020) |
| "These case reports aim to show that hyperfibrinogenemia is a risk factor for the progression and prognosis of peripheral arterial disease (PAD), in patients with and without diabetes mellitus type 2." | 3.88 | Hyperfibrinogenemia in Peripheral Arterial Disease: Coexistent and Independent Risk Factor (A Report of Two Cases and Review of Literature). ( Antova, E; Bosevska, G; Bosevski, M; Krstevski, G; Mitevska, I, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Golledge, J | 1 |
| Pinchbeck, J | 1 |
| Rowbotham, SE | 1 |
| Yip, L | 1 |
| Jenkins, JS | 1 |
| Quigley, F | 1 |
| Moxon, JV | 1 |
| Bosevski, M | 1 |
| Krstevski, G | 1 |
| Mitevska, I | 1 |
| Antova, E | 1 |
| Bosevska, G | 1 |
| Hermans, MP | 1 |
1 review available for fenofibrate and Peripheral Arterial Diseases
| Article | Year |
|---|---|
Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.
Topics: Albuminuria; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Evidence-Based Medicine; Fenofibrate; | 2011 |
2 other studies available for fenofibrate and Peripheral Arterial Diseases
| Article | Year |
|---|---|
Health-related quality of life amongst people diagnosed with abdominal aortic aneurysm and peripheral artery disease and the effect of fenofibrate.
Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal; Case-Control Studies; Cross-Sectional Studies; | 2020 |
Hyperfibrinogenemia in Peripheral Arterial Disease: Coexistent and Independent Risk Factor (A Report of Two Cases and Review of Literature).
Topics: Amputation, Surgical; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Fenofibrate | 2018 |